Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.
Visit the Open Targets Platform which provides an integration of public domain data to enable target identification and prioritisation.
Cambridge, 4 December 2017 – Open Targets announced today that Takeda has joined its pioneering public-private collaboration to transform drug discovery by improving the success rate for developing new medicines. Takeda is a global, research and development-driven pharmaceutical company with expertise in oncology, gastroenterology (GI) and central nervous system (CNS) disease that will complement the offerings of GSK, Biogen, the Wellcome Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), and build on the initiative’s success.
Generating and interpreting the data required to identify a good drug target demands a diverse set of skills, backgrounds, evidence types and technologies, which do not exist today in any single entity. Open Targets brings together expertise from five complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed.
Our goals are to:
We currently focus on oncology, immunology and neurodegeneration through an R&D framework that can be applied to all aspects of human disease. We believe that evidence generated in the most human relevant systems showing which targets are causing disease will have a significant impact on the successful development of new medicines. To build a good therapeutic hypothesis we need to find not only which targets are involved but also how we might alter complex disease mechanisms, and how predictive laboratory and animal results are for humans. Learn more about our science.
For more information about Open Targets please see this introductory video.